Comparison of the Efficacy of Generation 1 and 2 Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with EGFR Positive Mutations. (2021). Indian Journal of Forensic Medicine & Toxicology, 15(3), 4316-4324. https://doi.org/10.37506/ijfmt.v15i3.15970